Related Experiment Video
Updated: Mar 14, 2026
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
CD4-positive diffuse large B-cell lymphoma: A variant with aggressive clinical potential
Mohammad O Hussaini1, Friederike H Kreisel1, Anjum Hassan1
1Mohammad O Hussaini, Division of Molecular Pathology, Department of Pathology and Immunology, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, United States.
Abstract:
CD4 expression is rare in diffuse large B-cell lymphoma (DLBCL), with 4 previously reported cases. Its significance is uncertain. We report five patients with CD4(+) DLBCL and one CD4(+) primary mediastinal large B-cell lymphoma. Cases were identified by searching the electronic database of the department; each was reviewed. Average age was 56 years. Neoplastic cells expressed CD20 (5/6 tested cases). BCL2/BCL6 expression were seen in 3/3 tested cases, suggesting a germinal center origin. Additionally, expression of T-cell antigens CD2 and CD5 was noted in 2/2 and CD7 in 1/1 tested case. CD3 was negative in all. Lymph nodes were commonly involved (67%). Patients received chemotherapy +/- radiation (6/6) and bone marrow transplant (2/6). Average survival was 44.2 mo. CD4 expression in DLBCL raises questions of lineage commitment. CD4(+) DLBCL is rare; care should be exercised not to diagnose these as T-cell lymphomas. A subset behaves aggressively.
